Search results
Results from the WOW.Com Content Network
Chart of dependence potential and effective dose/lethal dose ratio of several psychoactive drugs. [89] Tolerance to psilocybin builds and dissipates quickly; ingesting psilocybin more than about once a week can lead to diminished effects. Tolerance dissipates after a few days, so doses can be spaced several days apart to avoid the effect. [6]
[14] [15] Studies of chronic cannabis users have demonstrated, although inconsistently, a long-lasting effect on the attention span, memory function, and cognitive abilities of moderate-dose, long-term users. Once cannabis use is discontinued for several months, these effects disappear, unless the user started consuming during adolescence.
When it comes to strain’s potential medical benefits, OG Kush, with its pain-relieving and relaxing effects, may be beneficial to individuals dealing with some form of physical discomfort.
A dried cannabis flower. The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol, and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
The effects last for two to six hours, depending on the amount used. At high doses, mental effects can include anxiety, delusions (including ideas of reference), hallucinations, panic, paranoia, and psychosis. There is a strong relation between cannabis use and the risk of psychosis, though the direction of causality is debated.
This is a partial list of herbs and herbal treatments with known or suspected adverse effects, either alone or in interaction with other herbs or drugs. Non-inclusion of an herb in this list does not imply that it is free of adverse effects.
Acute effects on the cerebellum manifest as changes in blood pressure, breathing rate, pulse rate, and loss of muscular coordination during intoxication. [8] PCP, like ketamine, also acts as a potent dopamine D 2 High receptor partial agonist in rat brain homogenate [43] and has affinity for the human cloned D 2 High receptor. [57]
THCV is a new potential treatment against obesity-associated glucose intolerance with pharmacology different from that of CB1 inverse agonists/antagonists. [13] GW Pharmaceuticals is studying plant-derived tetrahydrocannabivarin (as GWP42004) for type 2 diabetes in addition to metformin. [14] [better source needed]